自體免疫疾病體外診斷及實驗室自建市場（依檢測類型、技術、產品類型、最終用戶、應用及樣本類型分類）－2025-2032年全球預測

預計到 2032 年，自體免疫疾病的體外診斷和實驗室自建檢測市場將成長至 275.6 億美元，複合年成長率為 5.25%。

本文簡要說明了當前自體免疫免疫診斷領域，包括檢測方法創新、臨床應用促進因素以及對相關人員的策略意義。

診斷創新、不斷演進的臨床路徑以及臨床醫生對自體免疫疾病檢測準確性日益成長的需求，共同為診斷和檢測服務相關人員創造了一個關鍵時刻。本執行摘要概述了影響診斷工作流程和病人歷程的檢測平台最新進展、臨床醫生的應用模式以及體外診斷和實驗室自建檢測之間的相互作用。重點在於技術選擇、監管政策調整和實驗室運作模式如何影響檢測方法的選擇、分析性能以及後續的醫療協調。

診斷團隊和實驗室負責人在評估下一代檢測方法的應用時，必須權衡分析靈敏度和特異性與工作流程整合及報銷的實際情況。實驗室主任越來越重視那些既能縮短週轉時間又能保持臨床可靠性的檢測方法，而臨床醫生則在尋求能夠支持更快、更明確診斷的檢測手段。同時，製造商正在完善產品系列，以滿足血清學和生物標記檢測領域尚未滿足的需求，而學術中心則在拓展轉化醫學項目，以檢驗新的目標。

綜上所述，這些動態凸顯了產品開發、臨床檢驗和商業化策略協調一致的重要性。本摘要概述了領導者在製定循證醫學方案、最佳化實驗室營運以及與支付方和臨床醫生合作以提高診斷有效性和改善患者預後時應重點關注的戰略考慮因素。

檢測方法創新、監管動態和臨床工作流程現代化如何再形成自體免疫診斷並加速跨領域合作

近期的創新趨勢正在改變自體免疫疾病診斷的開發、檢驗和臨床應用方式。檢測化學和平台整合技術的進步提高了分析精度，而多重檢測能力則使得從單一樣本中進行廣泛的免疫分析成為可能。同時，實驗室正在積極採用自動化和數位化連接技術，以簡化工作流程並支援高通量檢測。

監管和報銷環境也在不斷變化，迫使製造商和實驗室加快進行強力的臨床檢驗並累積真實世界證據。這一趨勢有利於那些展現出實際臨床效用並能融入臨床醫師決策流程的檢測方法。實驗室自建檢測（LDT）與市售體外診斷試劑（IVD）的興起正在建構一個互補的生態系統：LDT通常能夠快速滿足特定或新興的臨床需求，而市售IVD則優先考慮標準化和擴充性。因此，臨床實驗室、學術研究中心和商業製造商之間的策略夥伴關係日益普遍，從而促進了生物標記向已驗證檢測方案的快速轉換。

此外，以病人為中心的照護模式以及臨床醫師對自體免疫異質性的認知不斷提高，凸顯了對更精準診斷演算法的需求。因此，相關人員增加對臨床醫生教育、多學科診斷通訊協定以及將血清學結果與臨床表現型聯繫起來的綜合報告的投入。總體而言，這種轉變正在推動自體免疫診斷朝著更協作、數據主導的方向發展，其中技術能力、證據生成和營運準備相互交織，共同決定著臨床應用。

評估2025年關稅調整對診斷供應鏈、籌資策略和區域製造決策的累積營運影響

2025年關稅政策調整及相關貿易措施為診斷劑和儀器組件的全球供應鏈引入了新的變數。這些關稅調整增加了製造商和實驗室採購的複雜性，促使他們重新評估籌資策略、庫存管理和供應商多元化。為此，許多相關人員探索了近岸外包方案和替代供應商關係，以降低進口成本波動和前置作業時間不確定性的風險。

為因應關稅變化，供應鏈做出了相應調整，促使製造商重新思考材料清單窗口，增加了關鍵耗材的緩衝庫存，並儘可能與全國或區域經銷商簽訂長期合約。這些營運調整強調了供應鏈的透明度和主動的供應商風險評估，同時確保了檢測的連續性。

此外，關稅環境促使各方就生產佈局和區域生產能力展開策略對話。一些公司加快了對區域製造和最終組裝能力的投資，以降低跨境風險；而另一些公司則專注於檢驗多家試劑供應商，以確保供應的連續性。總而言之，這些調整凸顯了貿易政策與診斷項目韌性之間的重要聯繫，並強調了情境規劃和靈活採購方式對於維持檢測和實驗室運作的必要性。

詳細的細分洞察揭示了測試類型、檢測技術、產品類型、最終用戶、臨床應用和樣本方式如何影響策略選擇。

細分市場分析揭示了不同檢測類型、檢測技術、產品類型、最終用戶、應用和樣本類型之間的差異化動態，這些動態會影響臨床效用、採購選擇和開發重點。檢測類型包括抗環瓜氨酸肽抗體、抗核抗體、乳糜瀉和類風濕因子，每種檢測類型都有其獨特的分析要求以及臨床醫生對特異性和可解釋性的期望。由於抗環瓜氨酸肽抗體具有預後價值，因此通常優先用於類風濕性關節炎的早期診斷。抗核抗體檢測通常用作篩檢工具，需要相應的演算法來指導預後診斷檢測。乳糜瀉的血清學檢測需要與病歷和基因檢測流程緊密結合，而類風濕因子檢測作為更廣泛的發炎檢測的一部分仍然具有重要價值。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• 採用高靈敏度抗CCP檢測方法對類風濕性關節炎患者進行風險分層
• 利用基於次世代定序的實驗室自建技術進行修格蘭氏症候群的個人化診斷
• 用於即時自體免疫生物標記定量分析的新興照護現場微流體平台
• 將機器學習演算法擴展到體外診斷工作流程中，以解讀複雜的自身抗體光譜。
• 實驗室開發的用於系統性紅斑狼瘡中抗雙股DNA抗體和補體蛋白多重檢測的檢測方法的發展
• 將數位免疫檢測與遠端醫療平台結合，用於遠端監測自體免疫疾病復發
• 為實現自體免疫疾病檢測實驗室自建檢測（LDT）臨床檢驗的標準化，監管機構正努力協調相關規定。
• 基於CRISPR技術的超靈敏檢測自體免疫相關基因突變的診斷工具的實現
• 高通量蛋白質體學在體外診斷試劑套件中的應用迅速成長，用於識別自體免疫疾病的新型生物標記
• 生技公司與診斷實驗室進行策略合作，共同開發針對自體免疫免疫疾病的實驗室自建檢測組合。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章自體免疫疾病體外診斷與實驗室自建市場（按檢測類型分類）

• 抗環瓜氨酸肽
• 抗核抗體
• 乳糜瀉
• 類風濕因子

第9章自體免疫疾病體外診斷與實驗室自建市場：依技術分類

• 化學冷光免疫檢測
• 酵素結合免疫吸附試驗
• 螢光免疫分析法
• 多重免疫檢測

第10章自體免疫疾病體外診斷與實驗室自建市場（依產品類型分類）

• 體外診斷試劑
• 實驗室開發測試

第11章自體免疫疾病體外診斷與實驗室自建市場（依最終用戶分類）

• 學術研究機構
• 診斷實驗室
• 醫院檢查室
• 參考實驗室

第12章自體免疫疾病體外診斷與實驗室自建市場：按應用領域分類

• 乳糜瀉
• 多發性硬化症
• 類風濕性關節炎
• 全身性紅斑性狼瘡
• 1型糖尿病

第13章自體免疫疾病體外診斷與實驗室自建市場（依樣本類型分類）

• 乾涸的血跡
• 電漿
• 血清
• 全血

第14章 各地區自體免疫疾病體外診斷及實驗室自建市場

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第15章自體免疫疾病體外診斷與實驗室自建市場（依組別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第16章 各國自體免疫疾病體外診斷與實驗室自建市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第17章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Siemens Healthineers AG
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • DiaSorin SpA
  • Quidel Corporation
  • EUROIMMUN AG

The IVD & LDT For Autoimmune Diseases Market is projected to grow by USD 27.56 billion at a CAGR of 5.25% by 2032.

A concise orientation to the current autoimmune diagnostics environment highlighting assay innovation, clinical adoption drivers, and strategic implications for stakeholders

The convergence of diagnostic innovation, evolving clinical pathways, and growing clinician demand for precision in autoimmune disease detection has created a pivotal moment for stakeholders across diagnostics and laboratory services. This executive summary distills recent advances in assay platforms, clinician adoption patterns, and the interplay between in vitro diagnostics and lab-developed tests that together shape diagnostic workflows and patient journeys. It centers on how technological choices, regulatory clarity, and laboratory operational models influence test selection, analytical performance, and downstream care coordination.

As diagnostics teams and laboratory leaders evaluate next-generation assay adoption, they must balance analytical sensitivity and specificity with workflow integration and reimbursement realities. Laboratory directors increasingly prioritize assays that reduce turnaround time while preserving clinical confidence, and clinicians seek tests that support earlier, more definitive diagnoses. Meanwhile, manufacturers refine product portfolios to address unmet needs in serology and biomarker detection, and academic centers expand translational programs to validate novel targets.

Taken together, these dynamics underscore the importance of aligning product development, clinical validation, and commercialization strategies. This summary outlines the strategic considerations that leaders should weigh when designing evidence generation plans, optimizing laboratory operations, and engaging payers and clinicians to improve diagnostic impact and patient outcomes.

How converging assay innovations, regulatory dynamics, and clinical workflow modernization are reshaping autoimmune diagnostics and accelerating cross-sector collaboration

Recent transformative shifts have altered how autoimmune disease diagnostics are developed, validated, and adopted across clinical settings. Advances in assay chemistries and platform integration have improved analytical precision, while multiplexing capabilities enable broader immunoprofiling from single samples. In parallel, laboratories are embracing automation and digital connectivity to streamline workflows and support high-throughput testing, which in turn affects turnaround times and capacity management.

Regulatory and reimbursement landscapes have also evolved, prompting manufacturers and laboratories to accelerate robust clinical validation and real-world evidence generation. These trends favor tests that demonstrate actionable clinical utility and that fit into clinicians' decision-making pathways. The rise of lab-developed tests alongside commercial in vitro diagnostics has created a complementary ecosystem: LDTs often address niche or emergent clinical needs quickly, while commercial IVDs prioritize standardization and scalability. Consequently, strategic partnerships between clinical laboratories, academic research centers, and commercial manufacturers have grown more common, facilitating faster translation of biomarkers into validated testing options.

Furthermore, patient-centric care models and increased clinician awareness of autoimmune heterogeneity emphasize the need for more precise diagnostic algorithms. As a result, stakeholders are investing in clinician education, multidisciplinary diagnostic protocols, and integrated reporting that links serologic results to clinical phenotypes. Overall, these shifts are driving a more collaborative, data-driven approach to autoimmune diagnostics, where technological capability, evidence generation, and operational readiness intersect to determine clinical adoption.

Assessing the cumulative operational consequences of 2025 tariff adjustments on diagnostic supply chains, sourcing strategies, and regional manufacturing decisions

Tariff policy adjustments and related trade measures introduced in 2025 have introduced new variables into global supply chains for diagnostic reagents and instrument components. These tariff developments increased procurement complexity for manufacturers and laboratories, prompting reassessments of sourcing strategies, inventory management, and supplier diversification. In response, many stakeholders examined nearshoring options and alternative supplier relationships to mitigate exposure to variable import costs and lead-time uncertainties.

Supply chain reactions to tariff changes encouraged manufacturers to revisit bill-of-materials strategies and to prioritize modular instrument designs that allow substitution of nonproprietary parts. Simultaneously, diagnostic laboratories adjusted procurement windows, increasing buffer inventories for critical consumables and negotiating longer-term agreements with domestic or regional distributors when feasible. These operational shifts, while preserving testing continuity, placed a premium on supply chain visibility and proactive supplier risk assessments.

Moreover, the tariff environment catalyzed strategic conversations about manufacturing footprint and regional capacity. Some firms accelerated investments in regional manufacturing and final assembly capabilities to reduce cross-border exposure, while others amplified their focus on validating multiple reagent suppliers to ensure continuity. Collectively, these adaptations underscore the critical link between trade policy and diagnostic program resilience, highlighting the need for scenario planning and agile procurement practices to sustain testing access and laboratory operations.

Detailed segmentation insights revealing how test types, assay technologies, product categories, end users, clinical applications, and sample modalities influence strategic choices

Segmentation analysis reveals differentiated dynamics across test types, technologies, product categories, end users, applications, and sample types that influence clinical utility, procurement choices, and development priorities. Based on Test Type, the landscape includes Anti Cyclic Citrullinated Peptide, Antinuclear Antibody, Celiac Disease, and Rheumatoid Factor, each presenting unique analytical requirements and clinician expectations for specificity and interpretability. Anti Cyclic Citrullinated Peptide assays are commonly prioritized for early rheumatoid arthritis diagnosis because their analytical characteristics support prognostic use, whereas Antinuclear Antibody testing often serves as a screening tool requiring reflex algorithms to guide follow-up testing. Celiac Disease serology necessitates tight integration with clinical history and genetic testing pathways, and Rheumatoid Factor testing retains value as part of broader inflammatory workups.

Based on Technology, stakeholders evaluate platforms including Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Fluorescence Immunoassay, and Multiplex Immunoassay when balancing throughput, sensitivity, and cost. Chemiluminescence Immunoassay platforms often appeal to high-volume laboratories seeking automated workflows and consistent performance, while Enzyme Linked Immunosorbent Assay remains a flexible option for lower throughput and centralized reference testing. Fluorescence Immunoassay can offer enhanced sensitivity for specific analytes, and Multiplex Immunoassay enables simultaneous profiling that supports differential diagnosis and research-grade immunophenotyping.

Based on Product Type, distinctions between In Vitro Diagnostic and Lab Developed Test pathways shape validation rigor, regulatory interaction, and commercial strategy. In Vitro Diagnostic solutions emphasize standardized kits and instrument integration to facilitate broad adoption, whereas Lab Developed Tests provide customization and rapid responsiveness to evolving clinical needs, especially in specialized centers. Based on End User, academic and research institutes, diagnostic laboratories, hospital laboratories, and reference laboratories each maintain different priorities related to validation depth, throughput, clinical integration, and payer relationships; academic centers drive translational validation, hospital laboratories focus on clinician alignment and rapid turnaround, and reference laboratories emphasize scale and centralized expertise.

Based on Application, reporting for Celiac Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Type 1 Diabetes demands tailored panels and interpretive frameworks that reflect disease-specific biomarker signatures and clinical algorithms. Clinicians increasingly expect tests to provide context-rich reports that integrate serologic patterns with likelihood assessments and recommended next steps. Finally, based on Sample Type, modalities such as Dried Blood Spot, Plasma, Serum, and Whole Blood affect collection logistics, stability considerations, and suitability for decentralized testing or remote sampling programs. Dried Blood Spot sampling supports outreach and decentralized screening initiatives, while plasma and serum remain predominant for high-sensitivity assays performed in centralized laboratories. These segmentation insights collectively inform product development priorities, clinical validation strategies, and commercialization approaches across the diagnostic ecosystem.

How distinct regulatory environments, payer frameworks, and clinical infrastructures across major regions determine diagnostic adoption patterns and strategic market entry

Regional dynamics shape adoption patterns, regulatory pathways, and commercial approaches in distinctive ways. Across the Americas, health systems vary from highly centralized national programs to mixed public-private models, and payer influence strongly shapes test reimbursement pathways and adoption velocity. Clinical practice guidelines and specialist networks in major markets drive clinician demand for specific autoimmune assays, and academic medical centers often lead translational validation that informs broader clinical adoption. Consequently, engagement strategies that align with local guideline development and payer evidence requirements tend to facilitate uptake.

In Europe, Middle East & Africa, the regulatory environment is heterogeneous, with some regions emphasizing centralized regulatory reviews and others maintaining national approval pathways. This diversity encourages modular regulatory and market entry strategies, alongside targeted clinical studies that address country-specific clinical practice patterns. Additionally, public health priorities and variable laboratory infrastructure across the region influence the feasibility of decentralized testing and the adoption of automated platforms versus reference lab models. Manufacturers and laboratories therefore balance regional evidence generation with flexible distribution partnerships.

Asia-Pacific markets demonstrate rapid uptake of innovative diagnostic technologies, supported by investments in clinical research infrastructures and expanding private laboratory networks. Diverse healthcare financing models and large patient populations create opportunities for both centralized reference testing and point-of-care initiatives, particularly when supported by remote-sampling approaches like Dried Blood Spot. Overall, regional strategies must account for regulatory complexity, payer frameworks, and local clinical practice to optimize adoption and align evidence generation with stakeholder expectations.

Strategic corporate and laboratory approaches highlighting platform expansion, evidence partnerships, and operational scaling that drive diagnostic credibility and clinical integration

Company strategies in autoimmune diagnostics reflect divergent priorities including platform innovation, partnerships, and service expansion to capture clinical demand and laboratory preference. Leading assay developers focus on expanding assay menus and enhancing platform interoperability to meet the needs of hospital laboratories and high-volume reference centers. These efforts often pair with strategic collaborations with academic institutions to validate novel biomarkers and to generate the clinical evidence necessary for guideline inclusion and payer consideration.

Laboratory groups and diagnostics service providers invest in expanding their LDT capabilities and in establishing centers of excellence for autoimmune testing, enabling rapid deployment of new assays and supporting clinician education. At the same time, developers of multiplex technologies emphasize the value proposition of comprehensive immunoprofiling for complex autoimmune presentations, targeting neurology and rheumatology centers that require broader serologic views for differential diagnosis. Mergers, acquisitions, and co-development agreements increasingly serve as mechanisms to accelerate entry into adjacent clinical segments and to access distribution networks in key regions.

Across commercial and laboratory stakeholders, there is a shared emphasis on evidence generation, interoperability, and scalable operations. Consequently, corporate investments prioritize clinical validation studies, real-world evidence programs, and post-market surveillance that demonstrate test performance in diverse patient cohorts. This focus enables companies and laboratories to align product positioning with clinician needs, regulatory expectations, and payer requirements, reinforcing diagnostic credibility and facilitating integration into care pathways.

Actionable strategic priorities for diagnostics and laboratory leaders to strengthen evidence, enhance resilience, and accelerate clinical adoption across care pathways

Industry leaders should adopt coordinated strategies that align assay development, evidence generation, and laboratory operations to accelerate clinical adoption and improve patient outcomes. First, prioritize clinical validation programs that demonstrate actionable utility in real-world patient cohorts, ensuring that study designs reflect clinician decision points and payer evidence needs. Simultaneously, invest in interoperability and workflow integration so that assays fit seamlessly into laboratory information systems and electronic health records, thereby minimizing friction for ordering clinicians and laboratory staff.

Second, diversify supply chains and consider regional manufacturing or final assembly to reduce exposure to trade-related disruptions. Building validated dual-source options for critical reagents and components will enhance operational resilience and support sustained testing capacity. Third, develop targeted engagement plans for key end users-academic centers for translational validation, hospital laboratories for operational fit, and reference laboratories for scale. These plans should include clinician education, interpretive reporting templates, and collaborative pilot programs that demonstrate clinical value.

Fourth, pursue partnerships to expand multiplexing capabilities and to develop integrated diagnostic algorithms that combine serologic results with clinical decision support. Finally, incorporate patient-centric sampling approaches, such as dried blood spot programs, to broaden access and to support decentralized testing initiatives. By implementing these recommendations, stakeholders can strengthen their competitive positioning while delivering diagnostics that align with evolving clinical workflows and patient care models.

A transparent, multi-source research methodology combining expert interviews, guideline synthesis, and reproducible analytical frameworks to generate actionable diagnostic insights

This research synthesizes multiple data sources, structured interviews, and a transparent analytical framework to ensure robust, reproducible findings. Primary qualitative inputs include interviews with clinical laboratory directors, assay developers, regulatory affairs specialists, and clinicians who treat autoimmune diseases, providing practical insights into validation practices, adoption barriers, and clinical decision drivers. These interviews informed thematic analysis and guided the selection of case studies that illustrate real-world integration of assays into diagnostic pathways.

Secondary inputs comprised peer-reviewed literature, clinical practice guidelines, and regulatory documentation that clarify analytic requirements and evidence expectations for both in vitro diagnostics and lab-developed tests. The methodological approach balanced depth and breadth by triangulating qualitative inputs with technical performance characteristics reported in the literature, paying particular attention to assay-specific validation metrics and sample type considerations. Data synthesis emphasized reproducibility, with cross-validation steps to reconcile discrepancies across sources and to ensure that interpretive claims reflect consensus where possible.

Analytical techniques included comparative validation mapping across technologies and test types, scenario-based supply chain impact assessment, and segmentation-driven insight generation to highlight actionable priorities for developers and laboratories. Throughout, we maintained clear documentation of assumptions and methodological choices, enabling clients to evaluate the applicability of findings to specific programs or geographies.

Concluding perspective on aligning innovation, evidence generation, and operational resilience to drive meaningful improvements in autoimmune disease diagnosis

In closing, the autoimmune diagnostics field stands at an inflection point characterized by higher expectations for analytical performance, tighter alignment between evidence generation and clinical utility, and greater operational scrutiny driven by supply chain realities. Stakeholders who integrate rigorous validation, seamless workflow compatibility, and resilient procurement strategies will be best positioned to translate technological advances into tangible clinical impact. The interplay of in vitro diagnostics and lab-developed tests offers a pragmatic dual-pathway where standardization and agility coexist to meet diverse clinical needs.

Leaders should focus on generating the right kinds of evidence to satisfy clinicians and payers, while investing in interoperability and interpretive reporting to enhance clinical utility. At the same time, supply chain diversification and regional capacity planning will remain critical to ensuring continuity of testing services. Taken together, these priorities suggest a roadmap where innovation, evidence, and operations align to support earlier and more accurate diagnosis, improved patient management, and more efficient laboratory workflows. Stakeholders who act decisively to address these areas will drive adoption and deliver value to clinicians, patients, and healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of high-sensitivity anti-CCP assays to stratify rheumatoid arthritis patient risk
• 5.2. Utilization of next-generation sequencing based LDTs for personalized Sjogren syndrome diagnostics
• 5.3. Emergence of point-of-care microfluidic platforms for real-time autoimmune biomarker quantification
• 5.4. Expansion of machine learning algorithms to interpret complex autoantibody profiles in IVD workflows
• 5.5. Growth of lab-developed assays for multiplex detection of anti-dsDNA and complement proteins in SLE
• 5.6. Integration of digital immunoassays with telehealth platforms for remote monitoring of autoimmune flares
• 5.7. Regulatory harmonization efforts for standardizing clinical validation of LDTs in autoimmune disease testing
• 5.8. Implementation of CRISPR-based diagnostic tools for ultra-sensitive detection of autoimmune-related gene variants
• 5.9. Surge in use of high-throughput proteomics in IVD kits to identify novel biomarkers for autoimmune pathogenesis
• 5.10. Strategic partnerships between biotech firms and diagnostic labs to co-develop targeted autoimmune LDT panels

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IVD & LDT For Autoimmune Diseases Market, by Test Type

• 8.1. Anti Cyclic Citrullinated Peptide
• 8.2. Antinuclear Antibody
• 8.3. Celiac Disease
• 8.4. Rheumatoid Factor

9. IVD & LDT For Autoimmune Diseases Market, by Technology

• 9.1. Chemiluminescence Immunoassay
• 9.2. Enzyme Linked Immunosorbent Assay
• 9.3. Fluorescence Immunoassay
• 9.4. Multiplex Immunoassay

10. IVD & LDT For Autoimmune Diseases Market, by Product Type

• 10.1. In Vitro Diagnostic
• 10.2. Lab Developed Test

11. IVD & LDT For Autoimmune Diseases Market, by End User

• 11.1. Academic And Research Institutes
• 11.2. Diagnostic Laboratories
• 11.3. Hospital Laboratories
• 11.4. Reference Laboratories

12. IVD & LDT For Autoimmune Diseases Market, by Application

• 12.1. Celiac Disease
• 12.2. Multiple Sclerosis
• 12.3. Rheumatoid Arthritis
• 12.4. Systemic Lupus Erythematosus
• 12.5. Type 1 Diabetes

13. IVD & LDT For Autoimmune Diseases Market, by Sample Type

• 13.1. Dried Blood Spot
• 13.2. Plasma
• 13.3. Serum
• 13.4. Whole Blood

14. IVD & LDT For Autoimmune Diseases Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. IVD & LDT For Autoimmune Diseases Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. IVD & LDT For Autoimmune Diseases Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Roche Diagnostics International AG
  • 17.3.2. Abbott Laboratories
  • 17.3.3. Thermo Fisher Scientific Inc.
  • 17.3.4. Danaher Corporation
  • 17.3.5. Siemens Healthineers AG
  • 17.3.6. bioMerieux SA
  • 17.3.7. Bio-Rad Laboratories Inc.
  • 17.3.8. DiaSorin S.p.A.
  • 17.3.9. Quidel Corporation
  • 17.3.10. EUROIMMUN AG

LIST OF FIGURES

• FIGURE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 167. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 168. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 169. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 170. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 238. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 241. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 244. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 245. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 246. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 247. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 249. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 253. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 254. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 255. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 258. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 259. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 261. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 266. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 267. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 268. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 274. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 275. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 280. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 281. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 282. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 283. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 284. ASEAN IVD & LDT